PD-L1 Expression in NSCLC: Clouds in a Bright Sky
International Journal of Molecular Sciences · 24.06.2025 · 26 (13) · 6066
DOI: 10.3390/ijms26136066 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.06.2025. Verfasst von Victoria Ferrari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Antoine Lacassagne Center, Department of Medical Oncology, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French national research agency, IDEX reference, “Investments for the Future” LABEX SIGNALIFE.
Abstract (Originalsprache)
Programmed Death-Ligand 1 (PD-L1) is a major target for immunotherapy using checkpoint inhibitors (CPIs), particularly in lung cancer treatment. Tumoral PD-L1 expression has been recognized as a natural predictor of CPI response. This predictive relationship is primarily due to its upregulation by interferon-gamma, which is released by immune cells (mainly T lymphocytes and natural killer cells) in proximity to tumor cells, driving an immune resistance mechanism. However, PD-L1 expression is modulated at multiple levels, including oncogenic signaling pathways, and transcriptional and post-transcriptional regulations, potentially leading to false positive predictions. Conversely, variable glycosylation of PD-L1 may compromise the accuracy of immunohistochemical measurements, resulting in false negative predictive data. In addition, PD-L1 expression demonstrates relative instability throughout treatment courses (e.g., chemotherapy and tyrosine kinase inhibitors), further limiting its clinical utility. In this review, we focused on the molecular mechanisms governing PD-L1 expression with a special emphasis on lung cancer. We also discussed biomarker strategies for optimizing patient selection for checkpoint inhibitor therapy where multimodal/multi-omics meta-biomarker approaches are emerging. Such comprehensive PD-L1-enriched biomarker strategies require evaluation through large-scale prospective studies, particularly in lung cancer, where numerous competing predictive candidates exist for CPI response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Antoine Lacassagne Center, Department of Medical Oncology, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France.
- Antoine Lacassagne Center, Department of Epidemiology and Biostatistics, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France.
- FHU OncoAge, IHU RespirERA, IRCAN, Inserm, CNRS 7284, U1081, University Côte d'Azur, 06189 Nice, France.
- Antoine Lacassagne Center, University Côte d'Azur, 33 Avenue de Valombrose, 06189 Nice, France.
ORCID-Profile: Victoria Ferrari, Jocelyn Gal, Baharia Mograbi
Förderung
- French national research agency
- IDEX reference
- “Investments for the Future” LABEX SIGNALIFE
Zitieren
APA
Ferrari, V., Gal, J., Mograbi, B., & Milano, G. (2025). PD-L1 Expression in NSCLC: Clouds in a Bright Sky. International Journal of Molecular Sciences, 26(13), 6066. https://doi.org/10.3390/ijms26136066
Vancouver
Ferrari V, Gal J, Mograbi B, Milano G. PD-L1 Expression in NSCLC: Clouds in a Bright Sky. International Journal of Molecular Sciences. 2025;26(13):6066. doi:10.3390/ijms26136066
BibTeX
@article{Ferrari2025,
author = {Ferrari, Victoria and Gal, Jocelyn and Mograbi, Baharia and Milano, Gerard},
title = {PD-L1 Expression in NSCLC: Clouds in a Bright Sky},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {13},
pages = {6066},
doi = {10.3390/ijms26136066}
}
EUVIMED